Camille A Huser

Prof. Camille A Huser


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
KBKaren Blyth
Karen Blyth
FVFrancois Vaillant
Francois Vaillant
AJAlma Jenkins
Alma Jenkins
LMLaura McDonald
Laura McDonald
MPMarie Anne Pringle
Marie Anne Pringle
ECEwan R. Cameron
Ewan R. Cameron

21 October 2010 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
GSG. P. Sandilands
G. P. Sandilands
MWM. Wilson
M. Wilson
CHCamille A Huser
Camille A Huser
LJL. Jolly
L. Jolly
WSW A Sands
W A Sands
CMC. McSharry
C. McSharry
The precise biological mechanisms that caused the TGN1412 clinical trial tragedy (also known as ‘The Elephant Man Clinical Trial’) in March 2006 remain a mystery to this day. It is assumed widely that the drug used in this trial (TGN1412) bound to CD28 on T lymphocytes and following activation of these cells, a massive ‘cytokine storm’ ensued, leading ultimately to multi-organ failure in all recipients. The rapidity of this in vivo response (within 2 h), however, does not fit well with a classical T lymphocyte response, suggesting that other ‘faster-acting’ cell types may have been involved. In this study we have activated purified human peripheral blood leucocyte populations using various clones of mouse monoclonal anti-CD28 presented to cells in the form of a multimeric array. Cytokines were measured in cell-free supernatants at 2 h, and specific mRNA for tumour necrosis factor (TNF)-α, thought to be the initiator of the cytokine storm, was also measured in cell lysates by reverse transcription–polymerase chain reaction (RT–PCR). Monocytes were the only cell type found to show significant (P < 0·05) up-regulation of TNF-α at 2 h. Eleven other monocyte cytokines were also up-regulated by anti-CD28 within this time-frame. It therefore seems likely that monocytes and not T cells, as widely believed, were probably responsible, at least in part, for initiating the cytokine storm. Furthermore, we propose that a multimeric antibody array may have formed in vivo on the vascular endothelium via an interaction between TGN1412 and CD64 (FcγRI), and we provide some evidence in support of this hypothesis.

27 February 2014 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
CHCamille A Huser
Camille A Huser
KGKathryn L. Gilroy
Kathryn L. Gilroy
JRJeroen de Ridder
Jeroen de Ridder
AKAnna Kilbey
Anna Kilbey
GBGillian Borland
Gillian Borland
JNJames Neil
James Neil
Retroviral insertional mutagenesis (RIM) is a powerful tool for cancer genomics that was combined in this study with deep sequencing (RIM/DS) to facilitate a comprehensive analysis of lymphoma progression. Transgenic mice expressing two potent collaborating oncogenes in the germ line (CD2-MYC, -Runx2) develop rapid onset tumours that can be accelerated and rendered polyclonal by neonatal Moloney murine leukaemia virus (MoMLV) infection. RIM/DS analysis of 28 polyclonal lymphomas identified 771 common insertion sites (CISs) defining a ‘progression network’ that encompassed a remarkably large fraction of known MoMLV target genes, with further strong indications of oncogenic selection above the background of MoMLV integration preference. Progression driven by RIM was characterised as a Darwinian process of clonal competition engaging proliferation control networks downstream of cytokine and T-cell receptor signalling. Enhancer mode activation accounted for the most efficiently selected CIS target genes, including Ccr7 as the most prominent of a set of chemokine receptors driving paracrine growth stimulation and lymphoma dissemination. Another large target gene subset including candidate tumour suppressors was disrupted by intragenic insertions. A second RIM/DS screen comparing lymphomas of wild-type and parental transgenics showed that CD2-MYC tumours are virtually dependent on activation of Runx family genes in strong preference to other potent Myc collaborating genes (Gfi1, Notch1). Ikzf1 was identified as a novel collaborating gene for Runx2 and illustrated the interface between integration preference and oncogenic selection. Lymphoma target genes for MoMLV can be classified into (a) a small set of master regulators that confer self-renewal; overcoming p53 and other failsafe pathways and (b) a large group of progression genes that control autonomous proliferation in transformed cells. These findings provide insights into retroviral biology, human cancer genetics and the safety of vector-mediated gene therapy. Cancers are known to arise by a series of mutational and non-mutational (epigenetic) events but the advent of cancer genome sequencing highlights the growing challenge of separating important (driver) from irrelevant (passenger) mutations. Retroviruses that induce cancer by inserting into host DNA and thereby altering key genes are valuable tools because they act as ‘tags’ to identify the critical targets. In this study we combined retroviral tagging with next generation sequencing to achieve a comprehensive description of lymphoma development and progression in transgenic mouse model systems. Our study suggests that three events may be sufficient for lymphoma development and identifies a genetic bottleneck at a small gene set that regulates tumour cell self-renewal, including the Myc oncogene and the p53 tumour suppressor. In contrast, many genes can provide the final step where the lymphoma cell acquires the ability to divide independently of external stimuli. As many of the target genes are conserved and play roles in cancers of non-viral origin, this study may provide a paradigm for the gene interactions that underlie cancer biology. It also elucidates the risks entailed in the recent use of retrovirus-based vectors for human gene therapy.

2 November 2022 in Education for Primary Care
Verified
Journal Article
Open access
MPMarina Politis
Marina Politis
MBMegan El Brown
Megan El Brown
CHCamille A Huser
Camille A Huser
LCLynsay Crawford
Lynsay Crawford
LPLindsey Pope
Lindsey Pope
Previous research has found a relationship between students’ gender and attitudes surrounding peer physical examination, but relationship between patient gender and confidence/comfort is less clear...

30 June 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Open access
PDF file
JHJodie Hay
Jodie Hay
KGKathryn Gilroy
Kathryn Gilroy
CHCamille A Huser
Camille A Huser
AKAnna Kilbey
Anna Kilbey
AMAlma Mcdonald
Alma Mcdonald
JNJames Neil
James Neil
MYC and RUNX oncogenes each trigger p53‐mediated failsafe responses when overexpressed in vitro and collaborate with p53 deficiency in vivo. However, together they drive rapid onset lymphoma without mutational loss of p53. This phenomenon was investigated further by transcriptomic analysis of premalignant thymus from RUNX2/MYC transgenic mice. The distinctive contributions of MYC and RUNX to transcriptional control were illustrated by differential enrichment of canonical binding sites and gene ontology analyses. Pathway analysis revealed signatures of MYC, CD3, and CD28 regulation indicative of activation and proliferation, but also strong inhibition of cell death pathways. In silico analysis of discordantly expressed genes revealed Tnfsrf8/CD30 , Cish , and Il13 among relevant targets for sustained proliferation and survival. Although TP53 mRNA and protein levels were upregulated, its downstream targets in growth suppression and apoptosis were largely unperturbed. Analysis of genes encoding p53 posttranslational modifiers showed significant upregulation of three genes, Smyd2 , Set , and Prmt5 . Overexpression of SMYD2 was validated in vivo but the functional analysis was constrained by in vitro loss of p53 in RUNX2/MYC lymphoma cell lines. However, an early role is suggested by the ability of SMYD2 to block senescence‐like growth arrest induced by RUNX overexpression in primary fibroblasts.

5 August 2021 in Journal of Perspectives in Applied Academic Practice
Verified
Journal Article
Closed access
CHCamille A Huser
Camille A Huser
SCSue Campbell
Sue Campbell
SFSamantha Fontaine
Samantha Fontaine
SJSusan Jamieson
Susan Jamieson
LMLeah Marks
Leah Marks
RYRonnie Young
Ronnie Young
In 2013, the University of Glasgow published an e-learning strategy, setting out a vision for the University’s digital education delivery between 2013 and 2020. The strategy’s aim, in part, was the creation of personalised, interactive and feedback-rich courses, and staff were noted as key enablers of the strategic priorities. As a result of this strategy, several initiatives were developed, including the creation of massive open online courses (MOOCs), the implementation of the Blended and Online Learning Development (BOLD) project, which led to the creation of fully online PGT masters programmes, blended Undergraduate courses, and eventually, the creation of a Digital Education unit. More recently, micro-credential courses have been developed, which bridge the gap between MOOCs and full online accredited programmes. Finally, in 2020, the COVID-19 pandemic led to the rapid pivot to remote teaching. In this article, we describe the roles, challenges and opportunities of early adopters in a number of these initiatives across the University, giving a reflective account of our lessons learnt and recommendations for staff involved in similar initiatives.